Discontinued — last reported Q4 '25
Belsomra — Sales
Merck & Co. Belsomra — Sales increased by 5.3% to $99.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.2%, from $89.00M to $99.00M. Over 4 years (FY 2021 to FY 2025), Belsomra — Sales shows a downward trend with a -12.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase in sales indicates successful market penetration, strong physician adoption, or effective marketing strategies, while a decrease may signal increased generic competition, patent expirations, or shifting clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product within the com...
Peer comparison
Comparable to product-specific revenue disclosures for mature or specialty drugs at other large-cap pharmaceutical companies.
mrk_segment_belsomra_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $155.00M | $162.00M | $162.00M | $137.00M | $138.00M | $124.00M | $117.00M | $112.00M | $126.00M | $116.00M | $108.00M | $93.00M | $106.00M | $156.00M | $89.00M | $100.00M | $79.00M | $94.00M | $99.00M |
| QoQ Change | — | +4.5% | +0.0% | -15.4% | +0.7% | -10.1% | -5.6% | -4.3% | +12.5% | -7.9% | -6.9% | -13.9% | +14.0% | +47.2% | -42.9% | +12.4% | -21.0% | +19.0% | +5.3% |
| YoY Change | — | — | — | — | -11.0% | -23.5% | -27.8% | -18.2% | -8.7% | -6.5% | -7.7% | -17.0% | -15.9% | +34.5% | -17.6% | +7.5% | -25.5% | -39.7% | +11.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s belsomra — sales?
- Merck & Co. (MRK) reported belsomra — sales of $99.00M in Q4 2025.
- How has Merck & Co.'s belsomra — sales changed year-over-year?
- Merck & Co.'s belsomra — sales increased by 11.2% year-over-year, from $89.00M to $99.00M.
- What is the long-term trend for Merck & Co.'s belsomra — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s belsomra — sales has grown at a -12.6% compound annual growth rate (CAGR), from $637.00M to $372.00M.
- What does belsomra — sales mean?
- The total revenue earned from the sales of a specific pharmaceutical product.